News
EDCTP and GHIT Fund partnership for the development of a pediatric formulation for schistosomiasis
The European & Developing Countries Clinical Trials Partnership (EDCTP) and the Japanese Global Health Innovative Technology Fund (GHIT) announced a new partnership today, 8 December 2017, to support product development research.
The partners’ first action will be co-funding the PZQ4PSAC phase III clinical study, which is sponsored by Merck KGaA and conducted by the Pediatric Praziquantel Consortium. Lygature is proud to have facilitated the partnership between the EDCTP and GHIT, and continues to provide independent program management for the Pediatric Praziquantel Consortium.
The study aims to provide clinical data and support for registration of a new praziquantel (PZQ) tablet formulation to treat schistosomiasis in preschool-aged children in sub-Saharan Africa.
Click here for the press release by EDCTP.
Click here for the press release by GHIT.